Medacta Reports on Device Utilization

Results from a 421-patient study revealed a 97.75% survival rate at 5 years for Medacta's AMIStem hip implant, suggesting that the device is a safe and reliable solution for cementless total hip arthroplasty (THA).

AMIStem system is often used with Medacta’s Anterior Minimally Invasive Surgery (AMIS) approach to THA. To date, AMIStem has been...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us